Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 7.07
HPTX's Cash to Debt is ranked lower than
60% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. HPTX: 7.07 )
Ranked among companies with meaningful Cash to Debt only.
HPTX' s 10-Year Cash to Debt Range
Min: 0.12  Med: 9.59 Max: N/A
Current: 7.07
Equity to Asset 0.72
HPTX's Equity to Asset is ranked higher than
53% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. HPTX: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
HPTX' s 10-Year Equity to Asset Range
Min: 0.5  Med: 0.84 Max: 0.87
Current: 0.72
0.5
0.87
F-Score: 4
Z-Score: 11.10
M-Score: 0.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1.53
HPTX's Operating margin (%) is ranked higher than
67% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. HPTX: -1.53 )
Ranked among companies with meaningful Operating margin (%) only.
HPTX' s 10-Year Operating margin (%) Range
Min: -31.79  Med: -17.75 Max: -3.7
Current: -1.53
-31.79
-3.7
Net-margin (%) -0.80
HPTX's Net-margin (%) is ranked higher than
67% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. HPTX: -0.80 )
Ranked among companies with meaningful Net-margin (%) only.
HPTX' s 10-Year Net-margin (%) Range
Min: -5.51  Med: 16.95 Max: 39.4
Current: -0.8
-5.51
39.4
ROE (%) -0.75
HPTX's ROE (%) is ranked higher than
72% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. HPTX: -0.75 )
Ranked among companies with meaningful ROE (%) only.
HPTX' s 10-Year ROE (%) Range
Min: -4.98  Med: 8.30 Max: 21.58
Current: -0.75
-4.98
21.58
ROA (%) -0.50
HPTX's ROA (%) is ranked higher than
74% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. HPTX: -0.50 )
Ranked among companies with meaningful ROA (%) only.
HPTX' s 10-Year ROA (%) Range
Min: -722.57  Med: -56.30 Max: 17.17
Current: -0.5
-722.57
17.17
ROC (Joel Greenblatt) (%) 223.68
HPTX's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. HPTX: 223.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HPTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -282757.89  Med: -42212.04 Max: 3698.48
Current: 223.68
-282757.89
3698.48
» HPTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

HPTX Guru Trades in Q3 2014

Joel Greenblatt 18,109 sh (New)
Jim Simons 118,000 sh (+243.02%)
» More
Q4 2014

HPTX Guru Trades in Q4 2014

Jim Simons 250,646 sh (+112.41%)
Joel Greenblatt 12,557 sh (-30.66%)
» More
Q1 2015

HPTX Guru Trades in Q1 2015

Paul Tudor Jones 10,764 sh (New)
Mario Gabelli 169,000 sh (New)
Jim Simons 316,000 sh (+26.07%)
Joel Greenblatt Sold Out
» More
Q2 2015

HPTX Guru Trades in Q2 2015

Mario Gabelli 611,100 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HPTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 43.86
HPTX's Forward P/E is ranked lower than
74% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. HPTX: 43.86 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 7.24
HPTX's P/B is ranked lower than
69% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. HPTX: 7.24 )
Ranked among companies with meaningful P/B only.
HPTX' s 10-Year P/B Range
Min: 3.23  Med: 4.32 Max: 7.25
Current: 7.24
3.23
7.25
P/S 7.81
HPTX's P/S is ranked higher than
58% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. HPTX: 7.81 )
Ranked among companies with meaningful P/S only.
HPTX' s 10-Year P/S Range
Min: 4  Med: 9.08 Max: 516.4
Current: 7.81
4
516.4
PFCF 34.32
HPTX's PFCF is ranked higher than
58% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. HPTX: 34.32 )
Ranked among companies with meaningful PFCF only.
HPTX' s 10-Year PFCF Range
Min: 13.22  Med: 17.64 Max: 40.65
Current: 34.32
13.22
40.65
POCF 33.33
HPTX's POCF is ranked lower than
51% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. HPTX: 33.33 )
Ranked among companies with meaningful POCF only.
HPTX' s 10-Year POCF Range
Min: 12.81  Med: 17.16 Max: 38.51
Current: 33.33
12.81
38.51
EV-to-EBIT 368.59
HPTX's EV-to-EBIT is ranked lower than
95% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. HPTX: 368.59 )
Ranked among companies with meaningful EV-to-EBIT only.
HPTX' s 10-Year EV-to-EBIT Range
Min: -472.9  Med: -28.70 Max: 25.7
Current: 368.59
-472.9
25.7
Current Ratio 4.19
HPTX's Current Ratio is ranked higher than
51% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. HPTX: 4.19 )
Ranked among companies with meaningful Current Ratio only.
HPTX' s 10-Year Current Ratio Range
Min: 0.11  Med: 5.39 Max: 11.32
Current: 4.19
0.11
11.32
Quick Ratio 4.04
HPTX's Quick Ratio is ranked higher than
51% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. HPTX: 4.04 )
Ranked among companies with meaningful Quick Ratio only.
HPTX' s 10-Year Quick Ratio Range
Min: 0.11  Med: 5.23 Max: 11.27
Current: 4.04
0.11
11.27
Days Inventory 95.96
HPTX's Days Inventory is ranked higher than
62% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. HPTX: 95.96 )
Ranked among companies with meaningful Days Inventory only.
HPTX' s 10-Year Days Inventory Range
Min: 95.12  Med: 101.63 Max: 108.14
Current: 95.96
95.12
108.14
Days Sales Outstanding 62.77
HPTX's Days Sales Outstanding is ranked higher than
50% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. HPTX: 62.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
HPTX' s 10-Year Days Sales Outstanding Range
Min: 38.22  Med: 43.00 Max: 47.77
Current: 62.77
38.22
47.77

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.77
HPTX's Price/Net Cash is ranked lower than
70% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. HPTX: 13.77 )
Ranked among companies with meaningful Price/Net Cash only.
HPTX' s 10-Year Price/Net Cash Range
Min: 4.32  Med: 5.66 Max: 13.74
Current: 13.77
4.32
13.74
Price/Net Current Asset Value 9.81
HPTX's Price/Net Current Asset Value is ranked lower than
61% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. HPTX: 9.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
HPTX' s 10-Year Price/Net Current Asset Value Range
Min: 4.22  Med: 5.16 Max: 9.79
Current: 9.81
4.22
9.79
Price/Tangible Book 7.68
HPTX's Price/Tangible Book is ranked lower than
64% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. HPTX: 7.68 )
Ranked among companies with meaningful Price/Tangible Book only.
HPTX' s 10-Year Price/Tangible Book Range
Min: 4.05  Med: 4.83 Max: 7.66
Current: 7.68
4.05
7.66
Price/Median PS Value 0.86
HPTX's Price/Median PS Value is ranked higher than
64% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. HPTX: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
HPTX' s 10-Year Price/Median PS Value Range
Min: 0.49  Med: 1.00 Max: 57.38
Current: 0.86
0.49
57.38
Earnings Yield (Greenblatt) (%) 0.30
HPTX's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. HPTX: 0.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HPTX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 4.40 Max: 5
Current: 0.3
0.3
5

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 125 146 178
EPS($) 1.14 1.05 2.52
EPS without NRI($) 1.14 1.05 2.52

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0HY.Germany,
Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for HPTX

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Horizon Pharma Net Rises 62%, Sales Double, Guidance Lifted May 08 2015
HYPERION THERAPEUTICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... May 07 2015
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings? - Analyst Blog May 07 2015
Horizon Pharma plc Completes Acquisition of Hyperion Therapeutics, Inc. May 07 2015
Horizon Pharma plc Announces Results of Tender Offer May 07 2015
HYPERION THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 06 2015
Horizon Pharma plc Announces Waiver of Financing Proceeds Condition Apr 30 2015
Horizon Pharma plc Announces Expiration of HSR Waiting Period for Proposed Hyperion Therapeutics,... Apr 29 2015
Great Point Partners Trims Its Stake In Alcobra Ltd (ADHD) Apr 22 2015
HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Hyperion... Apr 20 2015
Horizon Pharma PLC -- Moody's assigns B2 Corporate Family Rating to Horizon Pharma Apr 20 2015
IPO Summit Materials A Bright Spot In Ugly Session Apr 17 2015
HPTX INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of... Apr 13 2015
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of... Apr 10 2015
HYPERION THERAPEUTICS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... Apr 09 2015
HPTX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of... Apr 08 2015
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Apr 07 2015
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hyperion... Apr 06 2015
Stock Market News for April 06, 2015 - Market News Apr 06 2015
HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Hyperion... Apr 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK